Riding the pepTIDE — The Daily Wire on Therapeutic Peptides

An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.

Topic Sections

  • Top Shots — The most significant peptide and longevity stories ranked by overall editorial score
  • Research Signals — High-credibility scientific findings from journals, preprints, and clinical sources
  • Healing & Recovery — Tissue repair, injury recovery, and gut healing peptides including BPC-157 and TB-500
  • Growth Hormone Wire — Growth hormone secretagogues, peptide stacks, and GH axis research including Ipamorelin, CJC-1295, and MK-677
  • Metabolic & GLP-1 — Metabolic health, insulin sensitivity, and GLP-1 receptor agonist research including semaglutide and tirzepatide
  • Cognitive / Nootropic — Peptides targeting brain function, memory, neuroprotection, and cognitive enhancement
  • Skin & Cosmetic — Skin repair, anti-aging, collagen synthesis, and cosmetic peptide research including GHK-Cu and matrixyl
  • Reddit Finds — Community-sourced discussions, self-experimentation reports, and protocol threads from peptide communities
  • Contrarian Takes — Alternative viewpoints, dissenting research, and perspectives that challenge mainstream peptide narratives
  • Skeptic's Corner — Hype debunking, low-evidence alerts, and critical analysis of overstated peptide claims

Browse by Filter

  • Newest — Latest peptide and longevity stories
  • Most Credible — Highest credibility-scored stories
  • Most Edgy — High-novelty, unconventional findings
  • Most Discussed — Trending community discussions
  • Most Actionable — Direct applicability to daily health protocols
  • Lowest Risk — Stories with strong evidence, low hype
  • Research Only — Peer-reviewed and preprint studies
  • Reddit Only — Community discussion and anecdote
  • GLP-1 / Metabolic — Semaglutide, tirzepatide, and metabolic peptides
  • Healing / Recovery — BPC-157, TB-500, and repair protocols

More

  • About Riding the pepTIDE
  • Health Disclaimer
  • Submit a Source
  • Contact

Stalled on Mounjaro — Should I Keep Paying for No Weight Loss?

You’re asking a common question: you’ve been taking Mounjaro (a prescription drug for weight loss and diabetes) at 15 mg and your weight hasn’t budged for months, so you’re wondering whether to stop or keep paying for it. This is a real dilemma for a lot of people on these newer drugs: they work well at first, then hit a plateau. The quick answer is: don’t decide overnight—there are sensible steps to consider, and stopping abruptly may not be the best move. Talk to your prescriber before changing anything. Mounjaro is the brand name for tirzepatide. It’s a manufactured peptide (a small protein-like molecule) that acts on hormone receptors in your body to reduce appetite and help control blood sugar. Think of it as a chemical that mimics signals your gut and brain use to say “you’re full” and to regulate insulin. It’s given by injection and was studied for diabetes and weight loss. It’s not a one-time cure—its effects often depend on dose, time, diet, and other behaviors. What people report and what the studies show match up: many users see big weight drops in the first months, then slower progress or a plateau. Clinical trials show significant average weight loss, but individuals vary. Some people hit a steady state where weight holds for weeks or months. That stall can happen even though the drug is still working to reduce appetite and improve metabolism. The evidence on whether increasing dose, adding lifestyle tweaks, or switching drugs helps is mixed and personal. Most of the good data are from clinical trials with regular follow-up, not from uncontrolled self-experiments, so your doctor’s input matters. Why this matters to you: these drugs are expensive and require ongoing cost and planning. If you’re paying out of pocket and seeing no progress, it’s reasonable to reassess. But before quitting, consider whether the medication is still helping in other ways (less snacking, better blood sugar, less craving), whether lifestyle adjustments (diet, strength training, sleep, stress management) could break the plateau, or whether a dose change or different medication might help. A pause or stop can lead to weight regain; continuing might still preserve health gains even without more weight loss. Caveats and risks: don’t stop or change doses without talking to your prescriber. There can be side effects (nausea, diarrhea, gallbladder issues, rare pancreatitis) and some people can’t take or should avoid these drugs. Long-term safety and what happens when people stop are still being studied. Insurance coverage varies, and doctors can help weigh cost versus benefit. If you decide to stop, plan for it—work on sustainable habits and monitor any return of blood-sugar issues if you have diabetes. Bottom line: a plateau is common and not an automatic reason to quit, but it is a good trigger to review goals, side benefits, costs, and options with your clinician so you can make an informed choice.

Source: r/Mounjaro

Read full story

Back to Riding the pepTIDE